Pfizer (PFE) shares have shown some movement this week, drawing attention for investors evaluating the company’s current position and recent performance. The stock’s slight rebound over the past month ...

Mixed options sentiment in Pfizer (PFE), with shares up 30c, or 1.15%, near $26.00. Options volume roughly in line with average with 139k ...

Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus on the stock. Pfizer's performance has been mixed lately. Shares dipped ...

Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

Founded 170 years ago and currently headquartered in New York, Pfizer Inc. (PFE) is a global biopharmaceutical powerhouse ...

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become ...

Pfizer (NYSE:PFE) continued losses for seven consecutive sessions, as the stock closed 0.79% lower at $24.54 on Tuesday. In the preceding six sessions, the company lost over 6.4%. Shares of the ...

Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an ...

Pfizer propels itself into the obesity-drug game with $4.9 billion deal to buy Metsera. Shares of Metsera Inc. were rocketing into record territory in early Monday trading after the developer of ...

Shares of Pfizer rose after The Wall Street Journal reported the company would reveal a plan later Tuesday alongside the Trump Administration to lower drug costs. The stock rose 4% to $24.82. It is ...

The MarketWatch News Department was not involved in the creation of this content. -- Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's ...